We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Ask ADVFN Intelligence (AI)
Pro-Pharmaceuticals, Inc. (the ?Company?) (NYSE Alternext US: PRW), today provided an update regarding the company?s proposed rights offering, pre-New Drug Application (NDA...
Pro-Pharmaceuticals, Inc. (the ?Company?) (NYSE Alternext US: PRW) today has filed a registration statement with the Securities and Exchange Commission for its previously...
Pro-Pharmaceuticals, Inc. (NYSE Alternext US: PRW) announced that the Board of Directors has approved a rights offering to its shareholders whereby the Company will distribute...
Pro-Pharmaceuticals, Inc. (NYSE Alternext US: PRW) received?a letter dated?November 7, 2008 from the NYSE Alternext US (the "Exchange"), formerly known as the American Stock...
Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutics in the treatment of cancer and fibrosis, today...
Pro-Pharmaceuticals, Inc. (Amex: PRW) today announced that Theodore Zucconi, Ph.D., President, Pro-Pharmaceuticals, is scheduled to present a corporate update at the Rodman...
Pro-Pharmaceuticals, Inc. (Amex: PRW) today announced that a pre-New Drug Application (?NDA?) meeting with the U.S. Food & Drug Administration (?FDA?) is scheduled for...
The senior management of Pro-Pharmaceuticals, Inc. (AMEX: PRW), has outlined strategic initiatives that will reallocate corporate resources in order to extend the Company?s...
Pro-Pharmaceuticals, Inc. (Amex: PRW), today announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of...
Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutic compounds in the treatment of cancer and fibrosis...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
